Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

Multi-year distribution agreement with Australian Allografts

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that it has signed an exclusive distribution agreement with Australian Allografts for the distribution of the Tissue Regenix OrthoPure^® XT product in Australia and New Zealand. This is subject to regulatory approval from the Therapeutic Goods Administration ('TGA').

As part of the agreement, Australian Allografts and Tissue Regenix are mutually committed to achieving the TGA regulatory approval process to enable the import and distribution of the products. The initial distribution agreement is for three years and requires Australian Allografts to purchase a minimum unit volume each year after achieving the TGA approval.

The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL® technology and is the only available, non-human biologic graft for certain anterior cruciate ligament ('ACL') reconstruction procedures on the market. OrthoPure® XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.

Kirsten Lund, EMEA Business Director for Tissue Regenix, said: "This distribution agreement will allow physicians and patients better access to our innovative products through the Australian Allografts network and is another major step towards Tissue Regenix becoming a global player in the regenerative medicine market. We look forward to working with Australian Allografts."

Andrew Lambing, Managing Director for Australian Allografts, commented: "We are excited to partner with Tissue Regenix, bringing together two organisations with a clear focus for best patient outcome and delivering the latest technologies in tissue development and processing for Australia and New Zealand."

For more information:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.